Safety, Tolerability, Pharmacokinetics, and Time Course of Pharmacologic Response of the Active Metabolite of Roxifiban, XV459, a Glycoprotein IIb/IIIa Antagonist, following Oral Administration in Healthy Volunteers-Reference-Cited by-同舟云学术

Safety, Tolerability, Pharmacokinetics, and Time Course of Pharmacologic Response of the Active Metabolite of Roxifiban, XV459, a Glycoprotein IIb/IIIa Antagonist, following Oral Administration in Healthy Volunteers

Published:2002-07 Issue:7 Volume:42 Page:738-753
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Pieniaszek Henry J.,Sy Sherwin K. B.,Ebling William,Fossler Michael J.,Cain Valerie A.,Mondick John T.,Ma Su,Kornhauser David M.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference40 articles.

1. Platelet activation in unstable coronary disease;Fitzgerald;N Engl J Med,1986

2. A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials;Folts;J Am Coll Cardiol,1999

3. A platelet alpha granule membrane protein (GMP-140) is expressed on the plasma membrane after activation;Stenberg;Cell Biol,1985

4. Platelet membrane glycoprotein IIb/IIIa: member of a family of Asp-Gly-Asp-specific adhesion receptors;Pytela;Science,1986

5. Ligand binding to GP IIb-IIIa: a status report;Plow;Semin in Thromb Haemost,1992

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A general chemical principle for creating closure-stabilizing integrin inhibitors;Cell;2022-09

2. Enantioselective Mannich Reaction of Glycine Iminoesters with N-Phosphinoyl Imines: A Bifunctional Approach;Organic Letters;2019-10-14

3. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia;American Journal of Hematology;2007

4. Oral GPIIb / IIIa Antagonists: What Went Wrong?;Current Pharmaceutical Design;2004-05-01

5. Analysis Methods and Recent Advances in Nonlinear Pharmacokinetics from In Vitro through In Loci to In Vivo;Drug Metabolism and Pharmacokinetics;2004